利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

437 条记录 (耗时 0.023 秒)

    HBV mutations associated with reduced susceptibility to adefovir
    3.
    发明申请
    HBV mutations associated with reduced susceptibility to adefovir 审中-公开
    与阿德福韦敏感性降低相关的HBV突变

    公开(公告)号：US20040194155A1

    公开(公告)日：2004-09-30

    申请号：US10678443

    申请日：2003-10-01

    申请人： GILEAD SCIENCES, INC.

    发明人： William E. Delaney ,  Xiaofeng Xiong

    IPC分类号： A01K067/00 ,  A01K067/033 ,  C12N015/00 ,  C12N015/09 ,  C12N015/63 ,  C12N015/70 ,  C12N015/74 ,  C12N005/00 ,  C12N005/02

    CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/505 ,  C12N9/1276 ,  C12N2730/10122

    摘要： Applicants have identified 5 mutants associated with hepatitis B virus resistance to adefovir, a nucleotide analogue antiviral drug widely employed in the therapy of hepatitis B. In accord with this invention, reverse transcriptase mutants rtN236T, rtA181V, rtA181T and their corresponding surface antigen mutants sL173F and sL172trunc are provided. The mutant proteins, antibodies thereto and nucleic acids encoding the mutants have diagnostic value in monitoring and adjusting patient therapy with adefovir and in the therapy of patients infected with the mutants.

    摘要翻译： 申请人已经确定了与乙型肝炎病毒抗性相关的5种突变体，阿德福韦，广泛用于乙型肝炎治疗的核苷酸类似物抗病毒药物。根据本发明，逆转录酶突变体rtN236T，rtA181V，rtA181T及其相应的表面抗原突变体sL173F和 提供sL172trunc。 突变蛋白，其抗体和编码突变体的核酸在监测和调整阿德福韦的患者治疗以及感染突变体的患者的治疗方面具有诊断价值。

    Mitochondrial genome replenishment
    4.
    发明申请
    Mitochondrial genome replenishment 有权
    线粒体基因组补充

    公开(公告)号：US20040192627A1

    公开(公告)日：2004-09-30

    申请号：US10485407

    申请日：2004-01-30

    发明人： Volkmar Weissig ,  Vladimir Torchilin

    IPC分类号： A61K031/70 ,  A01N043/04 ,  C12N015/00 ,  C12N015/09 ,  C12N015/63 ,  C12N015/70 ,  C12N015/74

    CPC分类号： A61K48/00 ,  C12N15/87

    摘要： The invention provides composition and methods for delivering a composition according to the invention comprising a wild-type (wt) mitochondrial DNA (mtDNA) molecule to a mammalian cell. The wt-mtDNA molecule is a functional mtDNA molecule that includes the entire mitochondrial genome. The wt-mtDNA molecule in the composition of the invention has a mitochondrial leader sequence (MLS) peptide attached to facilitate the uptake of the mtDNA molecule into a mitochondrion of the mammalian cell. The delivery of the wt-mtDNA/MLS peptide complex is used as a general replenishment therapy for conditions attributed to mtDNA defects, independent of the specific defect in the mtDNA.

    摘要翻译： 本发明提供了将包含野生型（wt）线粒体DNA（mtDNA）分子的根据本发明的组合物递送至哺乳动物细胞的组合物和方法。 wt-mtDNA分子是包括整个线粒体基因组的功能性mtDNA分子。 本发明组合物中的wt-mtDNA分子具有连接的线粒体前导序列（MLS）肽，以促进mtDNA分子摄取到哺乳动物细胞的线粒体中。 将wt-mtDNA / MLS肽复合物的递送用作归因于mtDNA缺陷的条件的一般补充疗法，与mtDNA中的特异性缺陷无关。

    Novel adenoviral vector and methods for making and using the same
    7.
    发明申请
    Novel adenoviral vector and methods for making and using the same 有权
    新型腺病毒载体及其制备和使用方法

    公开(公告)号：US20040106193A1

    公开(公告)日：2004-06-03

    申请号：US09930832

    申请日：2001-08-15

    发明人： Mark A. Kay ,  Hiroyuki Mizuguchi

    IPC分类号： C12P021/06 ,  A61K039/12 ,  A61K039/23 ,  A61K039/235 ,  C12N015/00 ,  C12N015/09 ,  C12N015/63 ,  C12N015/70 ,  C12N015/74

    CPC分类号： C12N15/86 ,  A61K48/00 ,  C07K14/8125 ,  C12N2710/10343 ,  C12N2800/80

    摘要： In vitro methods for making a recombinant adenoviral genome, as well as kits for practicing the same and the recombinant adenovirus vectors produced thereby, are provided. In the subject methods, the subject genomes are prepared from first and second vectors. The first vector includes an adenoviral genome having an E region deletion and three different, non-adenoviral restriction endonuclease sites located in the E region. The second vector is a shuttle vector and includes an insertion nucleic acid flanked by two of the three different non-adenoviral vectors present in the first vector. Cleavage products are prepared from the first and second vectors using the appropriate restriction endonucleases. The resultant cleavage products are then ligated to produce the subject recombinant adenovirus genome. The subject adenoviral genomes find use in a variety of application, including as vectors for use in a variety of applications, including gene therapy.

    摘要翻译： 提供了制备重组腺病毒基因组的体外方法，以及用于实施其的试剂盒和由此产生的重组腺病毒载体。 在本发明方法中，从第一和第二载体制备受试者基因组。 第一载体包括具有E区缺失的腺病毒基因组和位于E区中的三个不同的非腺病毒限制性内切核酸酶位点。 第二载体是穿梭载体，并且包含侧翼于第一载体中存在的三种不同非腺病毒载体中的两个的插入核酸。 使用适当的限制性内切核酸酶从第一和第二载体制备裂解产物。 然后将所得裂解产物连接以产生本发明的重组腺病毒基因组。 主题腺病毒基因组可用于各种应用，包括用于各种应用的载体，包括基因治疗。

    Modified factor viia
    10.
    发明申请
    Modified factor viia 有权
    修饰因子viia

    公开(公告)号：US20040033566A1

    公开(公告)日：2004-02-19

    申请号：US10415963

    申请日：2003-05-05

    发明人： Wolfram Ruf ,  Ramona J Petrovan

    IPC分类号： C12P021/04 ,  C07H021/04 ,  C07K014/755 ,  A61K035/14 ,  C07K017/00 ,  C07K016/00 ,  C07K014/00 ,  C07K001/00 ,  C12N005/02 ,  C12N005/00 ,  C12N015/74 ,  C12N015/70 ,  C12N015/63 ,  C12N015/09 ,  C12N015/00 ,  C12P021/06

    CPC分类号： C07H21/04 ,  A61K38/4846 ,  C07K16/36 ,  C12N9/6437 ,  C12Y304/21021

    摘要： A modified factor VIIa is provided. The modified factor has increased amidolytic activity in the absence of T.F. and a higher affinity for T.F. when compared to the native factor VIIa but does not have substantially altered proteolytic activity when bound to T.F. Nucleic acid molecules that encode the factor, expression vectors that contain the nucleic acid molecules, cells that contain the nucleic acid molecules, and cells transformed with the expression vector are also provided. In a preferred embodiment, the modified factor is a human factor VIIa.

    摘要翻译： 提供了修饰因子VIIa。 在没有T.F的情况下，修饰的因子增加了酰胺分解活性。 并且对T.F.具有更高的亲和性。 当与天然因子VIIa相比时，当与T.F结合时，蛋白水解活性没有显着变化。 还提供了编码因子的核酸分子，含有核酸分子的表达载体，含有核酸分子的细胞和用表达载体转化的细胞。 在优选的实施方案中，修饰因子是人因子VIIa。